NGO · Belgium · EU Transparency Register 379847424451-15
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Among the 1106 non-governmental organisations on this site, they rank #310 by legislative files engaged, a count of participation, not a measure of influence.
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track International in PolicySpeak: request access →
Work at International Patient Organisation for Primary Immunodeficiencies (IPOPI)? so we know who speaks for it.
International Patient Organisation for Primary Immunodeficiencies (IPOPI) filed 5 positions between 14 Dec 2020 and 31 Oct 2025, across 4 of the 665 legislative files tracked here, attaching a full position paper 2 times.
IPOPI’s response to Commission’s consultation on draft proposal for the EU budget 2028-2034 IPOPI, the International Patient Organisation for Primary Immunodeficiencies, welcomes the European Commission’s ambition to strengthen the EU’s resilience and competitiveness under COM (2025) 570 final and the proposed European Competitiveness Fund (ECF).
Opening of the attached position paper · the full paper is on the Commission’s record (source link above)
The International Patient Organisation for Primary Immunodeficiencies (IPOPI) is the global patient organisation representing patients living with primary immunodeficiencies (PIDs). PIDs are genetic chronic and rare disorders (RD) in which the immune system does not work properly or at all.
The International Patient Organisation for Primary Immunodeficiencies (IPOPI) welcomes the opportunity to contribute evidence for the impact assessment on the proposed European Innovation Act. We provide our input from the perspective of patients living with primary immunodeficiencies (PIDs) across the European Union.
The International Patient Organisation for Primary Immunodeficiencies (IPOPI) welcomes the European Commission proposal for a Regulation on standards of quality and safety for substances of human origin (SoHO) intended for human application published in July 2022.
IPOPI represents patients with primary immunodeficiencies (PIDs), chronic and rare conditions in which the immune system does not work appropriately or at all. Around 60% of PID patients need immunoglobulin replacement therapies (Igs) throughout their lives to keep the levels of antibodies within a “normal” threshold to fight infections. No alternative treatments are available for these patients.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put International Patient Organisation for Primary Immunodeficiencies (IPOPI) next to another organization. Same files, same register facts, side by side. Compare →
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 80.
Everything on this page comes from International Patient Organisation for Primary Immunodeficiencies (IPOPI)’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.